A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study will help determine whether 2 doses of the combination (ipilimumab + nivolumab) is sufficient for patients with early benefit compared to the usual way of trying to give 4 doses. If patients do not show early benefit after 2 doses, patients will be able to continue with additional ipilimumab + nivolumab, even beyond the standard 4 doses if felt in the best interest of the patient.
Epistemonikos ID: bca87558a81ffdca7ad0a70a94bbcb1a71f7d88c
First added on: May 20, 2024